ReviewJournal of neurochemistry2016
Purines: forgotten mediators in traumatic brain injury.
Review in Journal of neurochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Pathological Roles of Astrocytes in Traumatic Brain Injury.CNS neuroscience & therapeutics · 2026Review
- The role of metabolomics in stroke: biomarkers of diagnosis and therapy.Metabolic brain disease · 2025Review
- Causal link between oxidative stress and epilepsy: A two-sample Mendelian randomization study.Brain and behavior · 2024Article
- Blood-Derived Metabolic Signatures as Biomarkers of Injury Severity in Traumatic Brain Injury: A Pilot Study.Metabolites · 2024Article
- The longitudinal biochemical profiling of TBI in a drop weight model of TBI.Scientific reports · 2023Article
- Identification of Serum Metabolites as Prognostic Biomarkers Following Spinal Cord Injury: A Pilot Study.Metabolites · 2023Article
- Recrystallization of Adenosine for Localized Drug Delivery.Molecular pharmaceutics · 2022Article
- Nanostructured carbon-fiber surfaces for improved neurochemical detection.Faraday discussions · 2022Article
- Cerebrospinal fluid purinomics as a biomarker approach to predict outcome after severe traumatic brain injury.Journal of neurochemistry · 2022Article
- Urinary metabolomic signatures as indicators of injury severity following traumatic brain injury: A pilot study.IBRO neuroscience reports · 2021Article
- Urinary biomarkers indicative of recovery from spinal cord injury: A pilot study.IBRO neuroscience reports · 2021Article
- Review
- Neuropathophysiological Mechanisms and Treatment Strategies for Post-traumatic Epilepsy.Frontiers in molecular neuroscience · 2021Review
- Paths to Successful Translation of New Therapies for Severe Traumatic Brain Injury in the Golden Age of Traumatic Brain Injury Research: A Pittsburgh Vision.Journal of neurotrauma · 2020Review
- Linking Traumatic Brain Injury, Sleep Disruption and Post-Traumatic Headache: a Potential Role for Glymphatic Pathway Dysfunction.Current pain and headache reports · 2019Review
- Membrane transporters in traumatic brain injury: Pathological, pharmacotherapeutic, and developmental implications.Experimental neurology · 2019Review
- 2',3'-cGMP exists in vivo and comprises a 2',3'-cGMP-guanosine pathway.American journal of physiology. Regulatory, integrative and comparative physiology · 2019Article
- Emerging Role of Purine Metabolizing Enzymes in Brain Function and Tumors.International journal of molecular sciences · 2018Review
- Coordination of ENT2-dependent adenosine transport and signaling dampens mucosal inflammation.JCI insight · 2018Article
- ABCG2 c.421C>A Is Associated with Outcomes after Severe Traumatic Brain Injury.Journal of neurotrauma · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Recently, the topic of traumatic brain injury has gained attention in both the scientific community and lay press. Similarly, there have been exciting developments on multiple fronts in the area of neurochemistry specifically related to purine biology that are relevant to both neuroprotection and neurodegeneration. At the 2105 meeting of the National Neurotrauma Society, a session sponsored by the International Society for Neurochemistry featured three experts in the field of purine biology who discussed new developments that are germane to both the pathomechanisms of secondary injury and development of therapies for traumatic brain injury. This included presentations by Drs. Edwin Jackson on the novel 2',3'-cAMP pathway in neuroprotection, Detlev Boison on adenosine in post-traumatic seizures and epilepsy, and Michael Schwarzschild on the potential of urate to treat central nervous system injury. This mini review summarizes the important findings in these three areas and outlines future directions for the development of new purine-related therapies for traumatic brain injury and other forms of central nervous system injury. In this review, novel therapies based on three emerging areas of adenosine-related pathobiology in traumatic brain injury (TBI) were proposed, namely, therapies targeting 1) the 2',3'-cyclic adenosine monophosphate (cAMP) pathway, 2) adenosine deficiency after TBI, and 3) augmentation of urate after TBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.